SEC Form 4 · accession 0001093557-17-000190
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew K Balo
Officer — EVP, Reg. Strategy, Clinical
Period of report
Sep 11, 2017
Accepted (ET)
Sep 13, 2017 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Sep 11, 2017 | S | 3,244 | $72.2692 | D | 96,813 | D | |
| Common StockF4,F3 | Sep 11, 2017 | D | 4,184 | $71.8134 | D | 92,629 | D | |
| Common StockF4,F3 | Sep 11, 2017 | D | 3,347 | $71.8134 | D | 89,282 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.
- F2This transaction was executed in multiple trades at prices ranging from $71.81 to $72.52. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F3Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018.
- F4These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.